Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil J Stone

Circulation

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Circulation|December 14, 2016
Looking Beyond Statins: Will the Dollars Make Sense?Neil J Stone
Circulation|October 20, 2004
Stopping statinsNeil J Stone
Circulation|March 31, 2012
Reducing residual risk in secondary prevention of cardiovascular diseaseNeil J Stone
Circulation|February 5, 2024
If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and UrgentNeil J Stone, Conrad Blum
Circulation|February 15, 2017
Potential for Net Benefit Should Guide Preventive TherapyNeil J Stone, Jennifer G Robinson
Circulation|April 7, 2020
Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on DyslipidemiaNeil J Stone, Roger S Blumenthal, Donald Lloyd-Jones, et al.
Circulation|April 7, 2020
Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on DyslipidemiaSalim S Virani, Sidney C Smith, Neil J Stone, et al.
Circulation|June 5, 2002
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valveNalini M Rajamannan, Malayannan Subramaniam, Margaret Springett, et al.
Circulation|December 28, 2018
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes TrialSalim S Virani, Julia M Akeroyd, Vijay Nambi, et al.
Circulation|July 14, 2004
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesScott M Grundy, James I Cleeman, C Noel Bairey Merz, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Circulation|December 14, 2016
Looking Beyond Statins: Will the Dollars Make Sense?Neil J Stone
Circulation|October 20, 2004
Stopping statinsNeil J Stone
Circulation|March 31, 2012
Reducing residual risk in secondary prevention of cardiovascular diseaseNeil J Stone
Circulation|February 5, 2024
If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and UrgentNeil J Stone, Conrad Blum
Circulation|February 15, 2017
Potential for Net Benefit Should Guide Preventive TherapyNeil J Stone, Jennifer G Robinson
Circulation|April 7, 2020
Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on DyslipidemiaNeil J Stone, Roger S Blumenthal, Donald Lloyd-Jones, et al.
Circulation|April 7, 2020
Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on DyslipidemiaSalim S Virani, Sidney C Smith, Neil J Stone, et al.
Circulation|June 5, 2002
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valveNalini M Rajamannan, Malayannan Subramaniam, Margaret Springett, et al.
Circulation|December 28, 2018
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes TrialSalim S Virani, Julia M Akeroyd, Vijay Nambi, et al.
Circulation|July 14, 2004
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesScott M Grundy, James I Cleeman, C Noel Bairey Merz, et al.
Pageof 2